Results 121 to 130 of about 3,401,781 (173)

1171 Understanding and mitigating the cytokine release syndrome (CRS) mediated by T cell bispecific antibody (TCB) treatment

open access: yesRegular and Young Investigator Award Abstracts
Claudio Schmidt   +6 more
openaire   +1 more source

Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use. [PDF]

open access: yesBlood Cancer Discov
Blumenberg V   +18 more
europepmc   +1 more source

Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma. [PDF]

open access: yesExp Hematol Oncol
Brooks C   +8 more
europepmc   +1 more source

Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma. [PDF]

open access: yesBlood Cancer J
Wang AX   +23 more
europepmc   +1 more source

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors. [PDF]

open access: yesFront Immunol
Lim JU   +17 more
europepmc   +1 more source

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation. [PDF]

open access: yesClin Pharmacol Ther
Li T   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy